Efficacy and safety of once‐daily insulin degludec/insulin aspart compared with once‐daily insulin glargine in participants with Type 2 diabetes: a randomized, treat‐to‐target study

AIMS: To investigate, in a 26‐week, open‐label, randomized, treat‐to‐target trial, the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily vs insulin glargine (IGlar) once daily in adults with Type 2 diabetes, inadequately controlled on basal insulin. METHODS: Participants we...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Diabet Med
Auteurs principaux: Kumar, S., Jang, H. C., Demirağ, N. G., Skjøth, T. V., Endahl, L., Bode, B.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2016
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5248644/
https://ncbi.nlm.nih.gov/pubmed/27027878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dme.13125
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires